U.S. clinical-stage immunotherapy company INmune Bio Inc. has priced its stock market listing at a price to the public of $8 per share, for gross proceeds of a minimum of $8 million and up to $20 million.
INmune Bio is offering a minimum of 1 million shares and up to 2.5 million shares to the public.
New York-based brokerage firm Univest Securities LLC is acting as the lead manager for the offering and institutional execution services provider WallachBeth Capital LLC and peer WestPark Capital Inc. are acting as co-managers.
Upon completion of the offering, INmune Bio’s common stock will be listed on the Nasdaq Capital Market under the ticker symbol INMB.